Treatment
SGLT2 inhibitor clinical trials
We’re tracking 41 recruiting studies that include SGLT2 inhibitor, each written for real people, not researchers, below.
Recruiting studies
- NCT07776054RecruitingPhase 4
SGLT2 inhibitor after heart shock for atrial fibrillation with heart failure
This study tests whether a diabetes drug called an SGLT2 inhibitor can help keep your heart in a normal rhythm after a procedure to shock it back into rhythm. It is for people with persistent atrial fibrillation and a type of heart failure where the heart is stiff.
Seoul, SeoulAges 19 years+ - NCT06668389RecruitingPhase 4
Testing a diabetes medicine for repaired tetralogy of Fallot
This study tests a type of diabetes medicine (SGLT2 inhibitor) to see if it can help people who had surgery for tetralogy of Fallot feel better and have stronger heart and lung function. It may be a good fit if you are an adult with repaired tetralogy of Fallot and do not have certain other health problems.
Hong KongAges 18 years+ - NCT06473844Recruiting
SGLT2 inhibitors for adults with sepsis
This trial tests whether a type of diabetes medicine (SGLT2 inhibitors) can help adults with sepsis, a life-threatening response to infection. If you have new-onset sepsis and can take oral medicine, you may be eligible.
Hong Kong, Hong KongAges 18 years+ - NCT04286399RecruitingPhase 4
Prevention trial for heart outcomes in people with type 2 diabetes
This Phase 4 trial studies an approach to help prevent heart problems in adults with type 2 diabetes who are at higher heart risk. It may help reduce future cardiovascular events by testing medications for safety and benefit in this group.
SingaporeAges 40 years+ - NCT06142474RecruitingPhase 3
SGLT2 inhibitors for heart failure patients during ventilator weaning
This trial tests a heart failure medication (SGLT2 inhibitor) to help people with heart failure who are on a breathing machine (ventilator) get better and come off the machine faster. It is for patients with a specific type of heart failure where the heart pumps weakly (EF ≤ 40%).
TaipeiAges 20 years+ - NCT07172971RecruitingPhase 1
SGLT2i drug for heart health in Duchenne muscular dystrophy
This trial tests if an SGLT2i medication can help protect heart function in people with Duchenne muscular dystrophy (DMD). The drug is already approved for other conditions, and researchers want to see if it can slow or prevent heart muscle damage.
Nashville, TennesseeAges 8–18 - NCT05770687Recruiting
Testing diabetes heart medicine soon after a heart attack
This study looks at how starting an SGLT2 inhibitor (a diabetes medicine) around the time of a heart attack affects heart outcomes and heart muscle changes over time. It may help you and your care team understand whether this timing is beneficial after a PCI procedure.
SeoulAges 19 years+ - NCT07436663RecruitingPhase 4
Preventing heart damage from breast cancer chemotherapy with two diabetes drugs
This trial tests whether two different diabetes drugs (SGLT-2 inhibitors and DPP-4 inhibitors) can help prevent heart damage that anthracycline chemotherapy can cause in breast cancer patients. You would receive one of the two drugs during your treatment to see if it protects your heart.
Tanta, ElgharbeyaAges Any age - NCT06838286Recruiting
Study of triple therapy for type 2 diabetes
This study looks at the safety and effectiveness of adding a third oral diabetes medicine to your current two-drug combination. It is for adults with type 2 diabetes whose blood sugar is not well controlled on metformin plus one other pill.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT02378805Recruiting
Alport syndrome registry to help delay kidney failure
This is a registry that collects information from people with Alport syndrome to better understand the disease and how to delay kidney failure. It may help researchers learn which factors and treatments are most important over time.
Göttingen, Lower SaxonyAges Any age - NCT07482943RecruitingPhase 4
Dapagliflozin for heart function after Fontan procedure
This trial tests whether dapagliflozin, a diabetes drug that also helps the heart, can improve exercise ability and heart function in people who have had the Fontan procedure for a single ventricle heart defect.
Hong KongAges 12 years+ - NCT05029115Enrolling by invitation
SGLT2 pill study for atrial fibrillation with type 2 diabetes
This trial tests whether an SGLT2 inhibitor pill can help people who have atrial fibrillation (an irregular heartbeat) and type 2 diabetes. You may be eligible if you’re in the right age range, on diabetes pills only, and meet specific heart and lab criteria.
Yangcheon, SeoulAges 20–80 - NCT07157475Recruiting
Blood vessel complications after leg artery procedures with SGLT2 inhibitors
This study looks at how a type of medicine called SGLT2 inhibitors (used for diabetes, kidney disease, or heart issues) affects blood vessel complications in people who have had a leg procedure to improve blood flow. It compares patients taking the medicine to those who are not.
Wroclaw, Lower Silesian VoivodeshipAges 18 years+ - NCT06291155RecruitingPhase 4
How SGLT2 inhibitors work in the kidneys for type 2 diabetes
This study tests how a drug called canagliflozin (an SGLT2 inhibitor) affects kidney function in people with type 2 diabetes. It involves two kidney biopsies to see how the drug works inside your kidneys, aiming to better protect kidney health.
Ann Arbor, MichiganAges 18–80 - NCT04899479RecruitingPhase 4
SGLT-2 inhibitor after heart attack to improve heart recovery
This trial studies whether starting an SGLT-2 inhibitor around the time of a heart attack can reduce heart damage size and improve how the heart heals. It focuses on people with a high risk of developing heart failure and who are getting a procedure to open blocked heart arteries.
SeoulAges 18 years+ - NCT05469659RecruitingPhase 2
Test drug to slow kidney damage in type 2 diabetes
This Phase 2 study compares tofogliflozin to metformin to see how well they reduce urine albumin levels (a marker of kidney stress) in people with diabetic kidney disease. You might benefit if your type 2 diabetes is affecting your kidneys despite standard blood-pressure medicines.
Matsumoto, NaganoAges 20 years+ - NCT07614230RecruitingPhase 4
SGLT2 drugs and heart artery health in diabetes
This study tests whether a diabetes medication called SGLT2 inhibitors can slow the buildup of plaque in heart arteries. Researchers will use special CT scans to track changes in your coronary arteries over time.
Beijing, Beijing MunicipalityAges 18–78 - NCT07572032RecruitingPhase 4
Delayed heart failure medications after fixing the cause
This study tests whether starting two heart failure medications later, after a procedure to fix the heart's problem, is safe and helpful. It aims to see if waiting a bit can still improve heart function and quality of life.
Daegu, DaeguAges 18 years+ - NCT06155604RecruitingPhase 2
SGLT2 inhibitor for lupus nephritis with kidney disease
This study tests if an SGLT2 inhibitor can help protect kidney function in people who have lupus nephritis (kidney inflammation caused by lupus) and chronic kidney disease (CKD). The goal is to see if this medicine can slow down further kidney damage.
Hong KongAges 18 years+ - NCT05345327RecruitingPhase 3
First diabetes pill to protect kidneys
This Phase 3 trial tests whether starting a diabetes medicine called dapagliflozin can better slow kidney damage than starting metformin in adults with type 2 diabetes. It may help preserve kidney function over time and reduce future kidney decline.
Sydney, New South WalesAges 18 years+ - NCT07491042Recruiting
A study of SGLT2 inhibitors for people on peritoneal dialysis
This study tests whether a type of diabetes medicine called SGLT2 inhibitors (which help lower blood sugar and protect the kidneys) can benefit people who are on chronic peritoneal dialysis. You may be able to join if you are 13 or older, have some urine output, and do not have certain other health issues.
NizwaAges 13 years+ - NCT07309094Recruiting
Effects of a diabetes drug on fat tissue in kidney disease
This trial tests whether a GLP-1 receptor agonist (a type of diabetes medication) can improve fat tissue health in people with chronic kidney disease who also have type 2 diabetes, cardiovascular disease, or obesity. It may help protect your kidneys and overall health.
Valencia, ValenciaAges 18–90 - NCT07237451Recruiting
Heart and kidney study of SGLT2 inhibitors
This study looks at whether a type of diabetes medicine called SGLT2 inhibitors (also known as flozins) can help protect the heart and kidneys in people with both heart failure with preserved pumping function and moderate chronic kidney disease, with or without diabetes.
IașiAges 18 years+ - NCT05852704RecruitingPhase 3
Dapagliflozin to prevent irregular heart rhythm after bypass surgery
This trial looks at whether dapagliflozin (a diabetes medicine that helps the kidneys and heart) can lower the chance of atrial fibrillation, an irregular heart rhythm, after coronary artery bypass (CABG) surgery. If you’re scheduled for planned bypass surgery, this study may help reduce post-operative rhythm problems.
BrnoAges 18 years+
What SGLT2 inhibitor is being studied for
Conditions with recruiting SGLT2 inhibitor studies.
Common questions
- Are there clinical trials studying SGLT2 inhibitor?
- Yes. Clin2 currently lists 41 recruiting studies that include SGLT2 inhibitor, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a SGLT2 inhibitor trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is SGLT2 inhibitor an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether SGLT2 inhibitor or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.